Occupational Activity – Page 33

Walgreens Expands into Specialty Pharmacy and Therapy Services

1 year ago talkbio0Tagged drug services, expansion, Health care facility, Services, specialty pharmacy, Walgreens

Walgreens, specialty pharmacy, drug services, therapy services, healthcare, expansion

Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal

1 year ago talkbio0Tagged Biopharma, CAR-T, Cellares, diversification, Generalized, Manufacture, Myers, Partner in relationship

Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal

Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma

1 year ago talkbio0Tagged Acquisition (action), Capacity, Eli Lilly, expansion, Facility (object), Injectables, Nexus Pharma, pharmaceutical manufacturing, production, strategic

Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.

AstraZeneca CEO Pascal Soriot’s Pay Rise Signals Succession Planning

1 year ago talkbio0Tagged AstraZeneca, CEO, Drug Industry, executive compensation, Pascal Soriot, Succession planning

AstraZeneca, Pascal Soriot, CEO, pay rise, succession planning, pharmaceutical industry, executive compensation.

Novartis Boosts 2024 Sales Forecast, Gears Up for Major Cancer Drug Expansions

1 year ago talkbio0Tagged 2024, cancer drugs, drug expansions, Drug Industry, Health care facility, Neoplasms, Novartis, Sales - occupational activity

Novartis, 2024 sales outlook, cancer drugs, drug expansions, pharmaceutical industry, healthcare, oncology.

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

Novartis Reevaluates Chinese Contractor Ties Amidst US Biosecurity Concerns

1 year ago talkbio0Tagged Biosecurity, CFO, Chinese contractors, Novartis, Relationships, U.S.

Novartis, Chinese contractors, US biosecurity, CFO, review, relationships, crackdown

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

1 year ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

23andMe Stock Surges as CEO Considers Taking Company Private

1 year ago talkbio0Tagged CEO, Privatization Plans, Science of genetics, Stock Jump

23andMe, Stock Jump, CEO, Privatization Plans, Genetics Company

Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

1 year ago talkbio0Tagged 2032, APOC3 gene, Arrowhead, cellular targeting, Dyslipidemias, Familial chylomicronemia syndrome, FCS, Fetal Bovine Serum, GlobalData, Plozasiran, Projections and Predictions, Sales - occupational activity, SHTG, Triglycerides, Unmet Needs

Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia